预约演示
更新于：2025-12-16
Esflurbiprofen
艾司氟比洛芬
更新于：2025-12-16
概要
基本信息
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C15H13FO2 |
InChIKeySYTBZMRGLBWNTM-JTQLQIEISA-N |
CAS号51543-39-6 |
关联
21
项与 艾司氟比洛芬 相关的临床试验CTIS2025-523577-42-00
Open label study to investigate patch adhesion of an Esflurbiprofen-containing patch in healthy volunteers
CTR20253906
评估受试制剂艾氟洛芬贴剂与参比制剂艾氟洛芬贴剂（Loqoa Tape）作用于健康成年受试者的吸收药代动力学研究
TCTR20240929002
Efficacy of Esflurbiprofen transdermal patch for postoperative analgesia in multilevel posterior lumbar spinal fusion: A randomized controlled trial
100 项与 艾司氟比洛芬 相关的临床结果
登录后查看更多信息
100 项与 艾司氟比洛芬 相关的转化医学
登录后查看更多信息
100 项与 艾司氟比洛芬 相关的专利（医药）
登录后查看更多信息
462
项与 艾司氟比洛芬 相关的文献（医药）2025-07-01JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
Development and Evaluation of an Innovative S‐Flurbiprofen‐Diethylamine Emulgel With Superior Transdermal Delivery and Analgesic Activity
Article
作者: Wang, Xingyin ; Hao, Chao ; Zhu, Xiaoqian ; Zhang, Guisen ; Zhang, Jian ; Yin, Chaoyang ; Yin, Mingyue ; Wang, Chenchen ; Xiao, Yang ; Zeng, Yuyu ; Han, Jinmeng ; Zhu, Anqi
ABSTRACT:
This study aimed to develop an innovative (S‐flurbiprofen)‐diethylamine (SFP‐DEA) emulgel formulation via incorporating SFP as the active pharmaceutical ingredient within a carbomer 940 gel matrix. SFP‐DEA emulgel was synthesized by dissolving SFP‐DEA in the aqueous phase of an oil‐in‐water (O/W) emulsion, followed by dispersion into a carbomer 940 gel matrix. The physicochemical stability of SFP‐DEA emulgel was evaluated via centrifuge, temperature swing test, high temperature, and long‐term storage at ambient conditions. Ex vivo SFP transdermal delivery of SFP‐DEA emulgel was evaluated using a Franz diffusion cell combined with excised rat skin. The in vivo analgesic activity and skin irritation test of SFP‐DEA emulgel were evaluated using a mouse knee osteoarthritis model and healthy rats, respectively. Results demonstrated that SFP‐DEA emulgel showed robust physicochemical stability and retain a final SFP content of 1.5% (w/w). Ex vivo transdermal study demonstrated that EMG5 (the emulgel optimized with laurocapram and menthol as penetration enhancers) achieved an 8‐h cumulative SFP transdermal flux of 741.28 μg/cm2 (44.23% of the administered dose), which is 27.94‐fold higher than that of Loqoa (SFP tapes). In addition, SFP‐DEA emulgel demonstrated rapid analgesic efficacy, with an 84.36% pain inhibition rate within 30 min in the osteoarthritis model, and elicited no signs of skin irritation in rats. In conclusion, the SFP‐DEA emulgel developed herein exhibits high stability, enhanced transdermal delivery, preliminary analgesic activity, and favorable safety profiles, positioning it as a promising topical therapeutic candidate.
2025-02-17ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Highly Efficient Chiral Separation Based on Alkali‐proof Protein Immobilization by Covalent Organic Frameworks
Article
作者: Yang, Mingfang ; Zhang, Sainan ; Zheng, Yunlong ; Yu, Jiangyue ; Guo, Jinbiao ; Zhang, Zhenjie ; Cai, Yuqing ; Chen, Yao ; Zuo, Along
Abstract:
Chiral separation plays a pivotal role in both practical applications and industrial productions. However, traditional chiral stationary phases (CSPs) exhibit inherent instability in alkaline environments, presenting a significant challenge despite their importance. Herein, basophilic alcalase is creatively developed to fabricate ultrastable protein‐based CSPs that can efficiently work under alkaline conditions. An in‐depth theoretical simulation is conducted to unveil the unique three‐dimensional conformation of alcalase, showing selective affinity towards various enantiomers of chiral amino acids and drugs, especially acidic substrates. Subsequently, an in situ assembly strategy is used to immobilize alcalase within a hydrazone‐linked covalent organic framework (COF) platform. The generated protein‐based CSPs enable successful baseline separation (Rs≥1.50) for various value‐added compounds (e.g., non‐steroidal drug, RS‐flurbiprofen; nucleotide analog, RS‐tenofovir) via high‐performance liquid chromatography, surpassing the commercial chiral column. Furthermore, a systematic study reveals that increasing hydrophilicity and pore sizes of COFs can enhance the separation performance. Remarkably, the obtained CSPs demonstrated exceptional durability, maintaining performance for >2,400 runs. This study provides a new member to the protein library for CSPs, and represents an innovative and effective platform for CSPs with immense potential for the enantioseparation of acidic drugs.
2025-02-01ANALYTICA CHIMICA ACTA
Preparation of novel chiral stationary phases based on chiral metal-organic cages enable extensive HPLC enantioseparation
Article
作者: Luo, Aiqin ; Duan, Juntao ; Tang, Bo ; Wang, Wei ; Zhang, Yukui ; Wang, Zhen ; Sun, Liquan ; Liang, Axin
BACKGROUND:
The metal organic cages (MOCs) are an emerging type of porous material that has attracted considerable research interest due to their unique properties, including good stability and well-defined intrinsic cavities. The chiral MOCs with porous structures have broad application prospects in enantiomeric recognition and separation. However, there are almost no relevant reports on chiral MOCs as chiral stationary phases (CSPs) for enantioseparation by high-performance liquid chromatography (HPLC).
RESULTS:
Here, we report for the first time, the chiral MOCs, MOC-PA was "wrapped" onto the silica gel to create a novel HPLC CSP of chiral MOC-PA@SiO2 through wrapped in net method. There are 24 and 20 chiral compounds or chiral drugs, including alcohols, diols, esters, ketones, alkene, epoxides, ethers, organic acids, phenols and amines, were enantioseparated by vary degrees on MOC-PA@SiO2 packed column under both normal phase (NP) and reversed phase (RP) modes, respectively. Furthermore, compared with commercial Chiralpak AD-H and Chiralcel OD-H columns, the MOC-PA@SiO2 packed column exhibits well chiral separation complementarity to them. It can separate some racemates that unable to be or not to be well separated by the Chiralpak AD-H and Chiralcel OD-H columns. Besides, there are four positional isomers were also well separated by MOC-PA@SiO2 packed column.
SIGNIFICANCE:
The effects of temperature and injection volume on separation of MOC-PA@SiO2 packed column were further investigated. This column also exhibited excellent repeatability, stability and column-to-column reproducibility on separation in HPLC. This work indicates that chiral MOCs are a promising class of chiral materials to prepare new CSPs for HPLC enantioseparation.
26
项与 艾司氟比洛芬 相关的新闻（医药）100 项与 艾司氟比洛芬 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 踝损伤 | 临床3期 | 德国 | 2025-03-31 | |
| 挫伤 | 临床3期 | 德国 | 2025-02-20 | |
| 疼痛 | 临床3期 | 德国 | 2025-02-20 | |
| 膝关节炎 | 临床3期 | 印尼 | 2018-02-05 | |
| 运动损伤 | 临床2期 | 德国 | 2021-05-20 | |
| 软组织损伤 | 临床2期 | 德国 | 2021-05-20 | |
| 扭伤和拉伤 | 临床2期 | 德国 | 2021-05-20 | |
| 急性疼痛 | 临床2期 | 美国 | 2016-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 200 | (Active Arm) | 遞膚網遞積鏇齋顧繭積(壓網糧範艱醖壓網壓獵) = 構鹹淵糧選鹹夢壓觸齋 衊壓獵願膚繭遞齋襯構 (網選繭築顧顧構齋衊遞, 11.1) 更多 | - | 2023-09-28 | ||
(Control Drug) | 遞膚網遞積鏇齋顧繭積(壓網糧範艱醖壓網壓獵) = 選衊膚壓壓簾艱蓋獵構 衊壓獵願膚繭遞齋襯構 (網選繭築顧顧構齋衊遞, 11.9) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用